These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Pathogenesis, prevention and therapy of steroid osteoporosis].
    Author: Dambacher MA, Olah AJ, Maurer H, Gampp R, Rüegsegger P.
    Journal: Z Orthop Ihre Grenzgeb; 1990; 128(3):234-9. PubMed ID: 2144069.
    Abstract:
    The pathogenesis of glucocorticoid osteoporosis is complex. Numerous, controversial mechanisms have been postulated. However, there is certainly both a reduction in bone formation as well as an increase in resorption. The increase in resorption probably occurs before the reduction in formation. As of a threshold dose of approx. 7.5% prednisone equivalents per day, administered for approx. 1 year, a loss of cancellous bone occurs; the reduction in compact bone is far less pronounced. Histologically, bone matrix synthesis appears to be uniformly reduced, while resorption varies considerably. The cancellous bone structure has a filigree appearance which is also recognizable by the glass-like appearance on radiographs. The development of new glucocorticoid preparations such as Deflazacort, which promotes osteoporosis less than, e.g., prednisone, is very promising. For the prevention and treatment of glucocorticoid-induced osteoporosis, frequently used drugs today are fluorides, ossein-hydroxy-apatite complexes and, especially in acute glucocorticoid osteoporosis, calcitonin.
    [Abstract] [Full Text] [Related] [New Search]